<DOC>
	<DOCNO>NCT00879047</DOCNO>
	<brief_summary>The propose study examine extent pharmacokinetic pharmacodynamic interaction alcohol various antiretroviral therapy HIV/AIDS , HIV/HCV co-infection , mild HCV healthy subject .</brief_summary>
	<brief_title>Interaction Alcohol Highly Active Antiretroviral Therapy ( HAART ) HIV/AIDS HIV/AIDS With Hepatitis C Virus ( HCV ) Co-Infection</brief_title>
	<detailed_description>The goal research study improve clinical care human immunodeficiency virus ( HIV ) -infected HIV/Hepatitis C ( HCV ) co-infected , alcohol-using patient identify significant interaction may occur drug commonly use treat HIV disease know cytochrome P450 ( CYP450 ) inducer inhibitor alcohol , frequently abused substance United States . We hypothesize concomitant use alcohol currently utilized antiretroviral therapy ( ART ) associate significant drug interaction include alteration alcohol ART pharmacokinetics well altered response alcohol administration . We plan conduct alcohol ART administration study 6 study sample ( n=10 ) : 1. HIV/AIDS eligible efavirenz-containing HAART , 2. HIV/AIDS eligible ritonavir-boosted protease inhibitor base HAART , 3. HIV/AIDS HCV eligible efavirenz-containing HAART , 4. HIV/AIDS HCV eligible ritonavir-boosted protease inhibitor regimen , 5. healthy subject take clinically relevant dos maraviroc 6. mild HCV take clinically relevant dos maraviroc . Pharmacokinetics , subjective , cognitive data serially collect course study session either alcohol placebo administer prior follow ART . Data collect elucidate presence clinical significance drug interaction , pharmacokinetic pharmacodynamic , alcohol ART population .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Participants diagnose HIV/AIDS , HIV/AIDS Hepatitis C , mild Hepatitis C healthy determine history physical examination , screen laboratory test urinalysis , eligible treatment HAART Participants experience alcohol consumption They may meet diagnostic criterion alcohol abuse nonphysiological alcohol dependence , may dependent substance include opioids , stimulant , cannabis , hallucinogens substance , prescribe illicit For HCV coinfection , HCV must stage consistent mild liver fibrosis ( fibrosis stage assess two method : AST platelet ratio ( APRI ) ( score &lt; 0.5 eligibility ) FIB4 fibrosis index ( score &lt; 1.5 eligibility ) , indicate mild liver disease . ) Age 21 old Hemoglobin Men &gt; 11 g/dL , Women &gt; 10 g/dL5 Able give voluntary , sign , informed consent . Patients receive concurrently drug inducer inhibitor hepatic microsomal enzyme Patients know sensitivity HIV therapeutic study Pregnant woman nurse mother . All woman sexually active capable become pregnant must negative pregnancy test within one week prior entry study . Major psychotic illness suicidality . Clinically active hepatitis liver enzyme elevation &gt; 3 time upper limit normal evidence liver fibrosis stage indicative great mild stage fibrosis ( see Inclusion Criteria ) . Those obesity ( BMI &gt; 30 ) , diabetes , hyperlipidemia , coagulation disorder , renal disease exclude . Hemoglobin Men &lt; 11 g/dL , Women &lt; 10 g/dL Physical dependence alcohol .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>